SUFFERING FROM DRY, ITCHY, RED OR BURNING EYES?

You are not alone. Between 30 to 40 million Americans are estimated to suffer from Dry Eye Disease. Meibomian Gland Dysfunction (MGD) is considered a leading cause in Dry Eye Disease, accounting for about 86% of cases. * Dry Eye Disease due to MGD can have a significant impact on your quality of life, leading to foreign body sensation, pain, blurry vision, dry or watery eyes. We know how tough and frustrating this can be – and you deserve a solution.

THE FIRST AND ONLY LIGHT THERAPY, FDA-APPROVED FOR DRY EYE MANAGEMENT

OptiLIGHT with Lumenis patented Optimal Pulse Technology uses precise, intense broad spectrum light to address the inflammation – one of the key underlining factors in dry eye disease due to MGD. OptiLIGHT is specifically developed to reach the delicate contours of the treated area safely, effectively and gently. OptiLIGHT sets new treatment standards and helps patients find a real solution for their dry eyes.

A REAL SOLUTION FOR DRY EYES

Backed by numerous clinical studies, OptiLIGHT’s novel Optimal Pulse Technology (OPT®) provides a transformative, safe, and efficacious way to improve signs of Dry Eye disease due to MGD. OptiLIGHT was designed for your peace of mind, delivering treatment that is safe and precise. Optimal results in just a few short sessions:

• A course of treatment typically includes 4 sessions spaced 2-4 weeks apart.
• Each session usually takes only 10-15 minutes.
• During the treatment your practitioner will apply a coupling gel on the treatment area and cover your eyes with shields.
• You may experience a warm sensation as light is applied to the skin, the treatment is gentle with minimum discomfort.
• OptiLIGHT is often followed by Meibomian Glands expression.

GENTLE, FAST, NO-DOWNTIME

Immediately following treatment, you may experience some redness. This will usually disappear within a few hours. You can return to your daily activities and apply makeup straight away in most cases. You will be advised to stay out of direct sunlight for a few days and to apply sunscreen. Patients usually report an improvement after their 2nd or 3rd treatment. Maintenance treatments are usually recommended every 6-12 months, to ensure the best long-term results.

RISK INFORMATION

Lumenis energy-based treatments are not suitable for everyone and, like every treatment, can carry some risks. Treatment with OptiLIGHT is contraindicated for patients with the following conditions in the treatment area: active infections, dysplastic nevi, tattoos, significant concurrent skin inflammation (excluding rosacea or acne), active cold sores, open lacerations, abrasions, and prolonged sun-exposure. Caution is advised for patients with a compromised immune system, coagulation disorders, photosensitivity, hormonal disorders, or a history of Herpes simplex neal the treatment area. Patients’ eyes must be occluded with eye shields during the treatment. Be sure to consult with your treatment provider to make sure that this treatment is the right choice for you.

SOURCES
1. Kassir et al. (2011) J Cosmet Laser Ther 13(5):216-22; | 2. Papageorgiou et al. (2008) Br J Dermatol 159(3):628-32; | 3. Liu et al. (2017) Am J Ophthalmol 183:81-90.; | 4. Yin et al. (2018) Curr Eye Res 43(3):308-13; | 5. Fishman et al. (2019) Photobiomodul Photomed Laser Surg 38(8):472-6 | 6. Lemp MA et al. (2012) Cornea 31(5):472-428; |7. Toyos et al. (2022) PLOS ONE 17(6)